Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Universal ResourcesFinancial_Report.xls
10-K - FORM 10-K - Universal Resourcesv328258_10k.htm
XML - IDEA: XBRL DOCUMENT - Universal ResourcesR5.htm
XML - IDEA: XBRL DOCUMENT - Universal ResourcesR2.htm
XML - IDEA: XBRL DOCUMENT - Universal ResourcesR3.htm
XML - IDEA: XBRL DOCUMENT - Universal ResourcesR4.htm
XML - IDEA: XBRL DOCUMENT - Universal ResourcesR7.htm
XML - IDEA: XBRL DOCUMENT - Universal ResourcesR6.htm
XML - IDEA: XBRL DOCUMENT - Universal ResourcesR9.htm
XML - IDEA: XBRL DOCUMENT - Universal ResourcesR8.htm
XML - IDEA: XBRL DOCUMENT - Universal ResourcesR1.htm
XML - IDEA: XBRL DOCUMENT - Universal ResourcesR10.htm
XML - IDEA: XBRL DOCUMENT - Universal ResourcesR12.htm
XML - IDEA: XBRL DOCUMENT - Universal ResourcesR11.htm
EX-31.1 - EXHIBIT 31.1 - Universal Resourcesv328258_ex31-1.htm
EX-32.1 - EXHIBIT 32.1 - Universal Resourcesv328258_ex32-1.htm
EX-31.2 - EXHIBIT 31.2 - Universal Resourcesv328258_ex31-2.htm

 

Exhibit 32.2

 

Chief Financial Officer Certification (Section 906)

 

 

CERTIFICATION PURSUANT TO

18 U.S.C., SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

 

 

Pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002), I, the undersigned Chief Financial Officer of Global Immune Technologies, Inc., (the “Company”), herby certify that, to the best of my knowledge, the Annual Report on Form 10-K of the Company for the period ended March  31, 2012 (the “Report”) fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. A signed original of this written statement required by Section 906 has been provided to the registrant and will be retained by it and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

Dated: October 31, 2012

 

 

  Global Immune Technologies, Inc.
   
  /s/ Jeffrey R. Bruhjell     
       CFO & PAO